Latest From BioAtla LLC
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research, Analytical Equipment and Supplies sectors. This month’s column covers deals announced December 2015 through January 2016.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2015.
BioAtla has entered a strategic and option agreement with Pfizer to develop a new class of antibody therapeutics, and plans to continue working with BioDuro as part of its R&D plans and efforts in China, which include a manufacturing site in Hefei. Meanwhile, BioAtla is also eyeing a possible IPO on Nasdaq next year.
ViroMed looks to bluebird to take its humanized antibody to the next steps of development in immuno-oncology. Takeda gets option for Cour's nanoparticle technology in Celiac disease, as well as up to three other indications.
Drug Discovery Tools
- Molecular Diversity
- Synthesis Technologies, Production Processes
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- North America
- Parent & Subsidiaries
- BioAtla LLC
- Senior Management
Jay M Short, PhD, Chmn., Pres. & CEO
Richard A Waldron, CFO
Michael Melnick, PhD, VP, Bus. Dev.
William Boyle, PhD, VP, Translational Med.
Cathy Chang, PhD, VP, R&D, Asia
- Contact Info
Phone: (858) 558-0708
11011 Torreyana Rd.
San Diego, CA 92121
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.